publication date: Feb. 15, 2019
Issue 7 - Feb. 15, 2019
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
  • Guest Editorial

    Making the case to double NIH

    The decision to double the budget of the National Institutes of Health should be easy, because it will save lives and save our economy simultaneously. The case for NIH is overwhelming, and there is broad bipartisan congressional support. So why is it so challenging?

  • NCI Director’s Report

    Sharpless: Please stay in oncology, don’t stop sending good research ideas to NCI

    The mathematical concepts underlying the challenge NCI is facing today aren’t difficult to grasp. In fact, a 14-year-old in an algebra class should be able to get it, NCI Director Ned Sharpless said to the National Cancer Advisory Board Feb. 12.

  • In Brief

    • Caryn Lerman named director at USC Norris Comprehensive Cancer Center
    • St. Baldrick’s and ACS form partnership focused on pediatric cancers
    • Report calls on US to accelerate the elimination of cervical cancer worldwide
  • TCCL Logo

  • Clinical Roundup

    • Keytruda + Inlyta improves OS, PFS and ORR vs. Sunitinib in RCC
    • Immunotherapy appears better than chemotherapy for skin cancer
    • Group of lymph nodes to determine prognosis for mesothelioma
    • Phase III ARCHES trial shows Xtandi improved PFS in prostate cancer
    • Opdivo + Yervoy shows continued survival benefit in RCC
    • Immunotherapy effective in recurrent glioblastoma
    • Black-white cancer mortality gap nearly eliminated in some age groups
    • Report calls on US to accelerate the elimination of cervical cancer worldwide
  • Drugs & Targets

    • European Commission approves Sprycel + chemo for pediatric
    • FDA grants Priority Review for Keytruda in head and neck squamous cell carcinoma
    • FDA accepts sBLA and grants Priority Review for Bavencio + Inlyta in RCC

Copyright (c) 2018 The Cancer Letter Inc.